200TiP A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa
| Autor: | S. Loibl, M. Reinisch, C. Denkert, P.A. Fasching, S. Seiler, T. Link, C. Hanusch, V. Bjelic-Radisic, A. Schneeweiss, J. Huober, C. Jackisch, K.E. Rhiem, M. Untch, C. Solbach, J-U. Blohmer, T. Buechele, V. Nekljudova, S. Loi |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Annals of Oncology. 33:S627 |
| ISSN: | 0923-7534 |
| DOI: | 10.1016/j.annonc.2022.07.235 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|